Filing Flows › Caribou Biosciences (CRBU) › Q1 2025
Caribou Biosciences (CRBU) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Caribou Biosciences (CRBU) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -3% from a year earlier and +13% from the quarter before.
Caribou Biosciences, Q1 2025: revenue $2.4M (-3% year over year), net loss $40.0M, operating cash flow −$36.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | +13% | -3% |
| Operating profit | −$42.9M | — | — |
| Net earnings | −$40.0M | — | — |
| Operating cash flow | −$36.7M | — | — |
What changed
Revenue was $2.4M in Q1 2025, down 3% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $42.9M, an operating margin of -1823.8%. Total costs fell 7% while revenue fell 3%. The quarter ended with a net loss of $40.0M, wider than the previous quarter's $35.5M loss.
Operating cash flow was −$36.7M. Non-cash charges added back $1.2M of depreciation and amortization and $3.9M of share-based compensation. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$37.8M.
Questions
What was Caribou Biosciences' revenue in the first quarter 2025?
Caribou Biosciences (CRBU) reported revenue of $2.4M for the first quarter 2025 (Q1 2025), -3% from a year earlier and +13% from the quarter before.